Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Josh Haimes"'
Autor:
Žaklina Strezoska, Abel Licon, Josh Haimes, Katie Jansen Spayd, Kruti M Patel, Kevin Sullivan, Katarzyna Jastrzebski, Kaylene J Simpson, Devin Leake, Anja van Brabant Smith, Annaleen Vermeulen
Publikováno v:
PLoS ONE, Vol 7, Iss 8, p e42341 (2012)
RNAi screening using pooled shRNA libraries is a valuable tool for identifying genetic regulators of biological processes. However, for a successful pooled shRNA screen, it is imperative to thoroughly optimize experimental conditions to obtain reprod
Externí odkaz:
https://doaj.org/article/eb94d0add74e441f93937a750fe12195
Autor:
Giulia Corbet, Philip Benson, Kailee Reed, Skyler Mishkin, Thomas Harrison, Kristin Scott, Zane Jaafar, Kristina Giorda, Josh Haimes, Martin Ranik, Brian Kudlow
Publikováno v:
Cancer Research. 83:215-215
Clinical oncology heavily relies on formalin-fixed, paraffin-embedded (FFPE) tissue samples for histology and molecular characterization. The chemical and physical modifications of nucleic acids introduced during fixation, storage and purification ne
Autor:
Zane Jaafar, Josh Haimes, Thomas Harrison, Lindsay Peterkin, Martin Ranik, Kristin Scott, Brian A. Kudlow
Publikováno v:
Cancer Research. 82:2288-2288
After a decade of NGS technology and workflow innovation, personalized medicine is starting to become a reality. DNA fragmentation is still a critical bottleneck during library preparation. Sonication methods have been the gold standard for consisten
Autor:
Krista Hu, Abel Licon, Aaron M Berlin, Erroll H. Rueckert, Valentina Nardi, Abner Louissaint, Maggie Y Pontius, Briana Hudson, Rory Crotty, Kristen E. Stevenson, Matt Rodenbaugh, Josh Haimes, Russell J.H. Ryan, A. John Iafrate, Aliyah R. Sohani, Heather Ann Brauer
Publikováno v:
Am J Clin Pathol
Objectives Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma with a heterogenous genetic landscape that can require multiple assays to characterize. We reviewed a 1-step RNA-based assay to determine cell of origin (COO), det
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ecbc2a46753767ffe0f261f747cf2db
https://europepmc.org/articles/PMC8244124/
https://europepmc.org/articles/PMC8244124/
Autor:
Ann Whitehouse, Nichola Cope, May Ying Leong, Skyler Mishkin, Colin J.R. Stewart, Cheng-Han Lee, Brian Kudlow, Josh Haimes, Martin Köbel, W. Glenn McCluggage, Rola H. Ali, Sung Hock Chew, Eleanor Koay, Nissreen Mohammad
Publikováno v:
American Journal of Surgical Pathology. 42:1353-1359
Inflammatory myofibroblastic tumor (IMT) is a myofibroblastic/fibroblastic neoplasm of intermediate malignant potential. It is frequently characterized by genetic fusion of ALK with a variety of partner genes, which results in the activated ALK signa
Autor:
Heather Ely, Jeeyun Lee, Aaron Boomer, Diane R. Fernandez, Danielle Murphy, Kyoung-Mee Kim, Ian Hoskins, Josh Haimes, Jason Christiansen, Brady P. Culver, Jennifer Lamoureux, Ryan D. Walters, Robert H. Shoemaker, Joshua Stahl
Publikováno v:
Applied Immunohistochemistry & Molecular Morphology
Supplemental Digital Content is available in the text.
Targeted therapy combined with companion diagnostics has led to the advancement of next-generation sequencing (NGS) for detection of molecular alterations. However, using a diagnostic test t
Targeted therapy combined with companion diagnostics has led to the advancement of next-generation sequencing (NGS) for detection of molecular alterations. However, using a diagnostic test t
Autor:
W. Glenn McCluggage, Eleanor Koay, Brian A. Kudlow, Jen-Chieh Lee, Tony Ng, Josh Haimes, Cheng-Han Lee, Colin J.R. Stewart, Bo Meng, Brady P. Culver, Ann Whitehouse, Nichola Cope
Publikováno v:
American Journal of Surgical Pathology. 41:773-780
Inflammatory myofibroblastic tumor (IMT) can occur in a number of anatomic sites, including the uterus. Like its soft tissue counterpart, uterine IMT frequently expresses ALK and harbors ALK genetic rearrangements. The aim of this study is to fully c
Autor:
Volker Endris, Cathleen Nientiedt, Fabian Stögbauer, Carsten Grüllich, Dirk Jäger, Adam Kaczorowski, Markus Hohenfellner, Stefanie Zschäbitz, Holger Sültmann, Maximilian Jenzer, Brian Kudlow, Skyler Mishkin, Anna-Lena Volckmar, Peter Keß, Anette Duensing, Maximilian Kippenberger, Stefan Duensing, Josh Haimes, Peter Schirmacher, Albrecht Stenzinger, Jonas Leichsenring
Publikováno v:
Cancer Immunology, Immunotherapy
Defects in DNA damage repair caused by mutations in BRCA1/2, ATM or other genes have been shown to play an important role in the development and progression of prostate cancer. The influence of such mutations on anti-tumor immunity in prostate cancer